Leishmaniasis, a category 1 disease, has remained neglected for decades, and therefore,
has developed into a severe health problem worldwide. Unfortunately, the available …

The present review focuses on a dreaded vector-mediated leishmaniasis, with the existing
therapeutic approaches including a variety of drugs along with their limitations, the treatment …

Visceral leishmaniasis (VL) or kala-azar is a vector borne infectious disease caused by the
protozoan parasites of the genus Leishmania. VL is endemic in more than 85 countries with …

Leishmaniasis is a syndrome caused by the protozoan parasites which is transmitted by the
bite of the female sand fly. The disease has three major forms: Cutaneous, Mucocutaneous …

Leishmaniasis, a vector-borne disease caused by obligate intramacrophage protozoa,
threatens 350 million people in 98 countries around the world. There are already 12 million …

Leishmaniases are infectious diseases caused by an intracellular protozoan in humans by
20 different species of Leishmania among more than 53 species. There are at least twelve …

Leishmaniasis is a widespread disease that causes 20,000 to 30,000 deaths annually,
making it a major health problem in endemic areas. Because of low-performance …

Nanobiotechnology is an important field with many new applications. This opportunity has
been greatly embraced by the medical research community in the continuous search of …

Many recent key innovations in nanotechnology have greatly fascinated scientists to explore
new avenues in treatment and diagnosis of emerging diseases. Due to extensive utilization …

Resistance to antileishmanial drugs such as sodium stibogluconate (SSG), amphotericin B
(Amp-B), and miltefosine is on the rise, and alternate strategies for effective treatment have …